Trade Agreement: CETA / WTO-AGP / NAFTA / CFTA / FTAs with Peru / Colombia / Panama / Korea
Tendering Procedures: All interested suppliers may submit a bid
Competitive Procurement Strategy: Lowest/Lower Bid
Comprehensive Land Claim Agreement: No
Nature of Requirements:
Stabilized Whole Blood Product
6D063-174330/A
Rumbolt, Ian
Telephone No. - (204) 260-9623 ( )
Fax No. - (204) 983-7796 ( )
Public Health Agency Canada's Quality Assessment and Standardization for Immunological (QASI) measures relevant to HIV/AIDS requires an assayed whole blood quality control product containing stabilized human red blood cells and white blood cells in a preservative medium. The assayed whole blood quality control product must be supplied in two clinically-relevant levels of CD4 cells. Assayed whole blood quality control product, in two clinically-relevant levels of CD4 cells will be purchased three times each year. The product will be shipped in 750uL custom-labelled vials to the National Laboratory for HIV Immunology Section located at the JC Wilt Infectious Diseases Centre.
The resulting Standing Offer will be from approximately June 1, 2018 to May 31, 2019 with three, one year option periods.
The requirement is subject to the provisions of the World Trade Organization Agreement on Government Procurement (WTO-AGP), the North American Free Trade Agreement (NAFTA), and the Canadian Free Trade Agreement (CFTA).
Delivery Date: Above-mentioned
The Crown retains the right to negotiate with suppliers on any procurement.
Documents may be submitted in either official language of Canada.
